Lung Transplant Clinical Trials

Clinical trials related to Lung Transplant Procedure

Analysis of Vaccine-induced Immune Responses and Optimization of Protective Immunity Against Respiratory Syncytial Virus in Lung Transplant Recipients

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:

• Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study

• Recipients of a lung transplant who are receiving immunosuppressive therapy to prevent allograft rejection.

• Adults aged 60 years or older who voluntarily provide written informed consent to participate in the study.

• Individuals who do not have medical conditions associated with immunocompromise (e.g., malignancy, bone marrow transplantation, solid organ transplantation, HIV infection, or dialysis) and have not received ongoing chemotherapy, radiation therapy, immunosuppressive therapy, or immunomodulatory therapy within 6 months before vaccination.

Locations
Other Locations
Republic of Korea
Seoul National University Hospital
RECRUITING
Seoul
Contact Information
Primary
Chan Mi Lee, M.D., PhD.
heaven229@naver.com
82-2-2072-1473
Backup
Young Hoon Hwang, M.D.
hyh0307@gmail.com
82-2-2072-2228
Time Frame
Start Date: 2026-10
Estimated Completion Date: 2028-10
Participants
Target number of participants: 80
Treatments
Experimental: Lung transplant recipient
Lung transplant recipients aged ≥19 years receiving immunosuppressive therapy (n=60)
Active_comparator: Control
Immunocompetent adults aged ≥60 years (n=20)
Related Therapeutic Areas
Sponsors
Leads: Seoul National University Hospital

This content was sourced from clinicaltrials.gov